-
Special Interest Groups
- Biosimilars
- Clinical Outcome Assessment
- Digital Health
- Health Preference Research
- Medical Devices and Diagnostics
- Medication Adherence and Persistence
-
Nutrition Economics
- Oncology
- Open Source Models
- Patient-Centered
- Personalized / Precision Medicine
- Rare Disease
- Real-World Evidence (RWE)
- Statistical Methods in HEOR
-
Task Forces
- Machine Learning Methods in HEOR
- Measurement Comparability Between Modes of Administration of PROMs
- Performance Outcome (PerfO) Assessments
- Systematic Reviews with Cost and Cost-Effectiveness Outcomes
- Value Assessment Frameworks Special Task Force
- Value of Information Analysis for Research Decisions
- Joint ISPE-ISPOR Special Task Force
- Councils & Roundtables
-
Global Groups
-
Consortia
-
Asia Consortium
- Asia Consortium Founding Members
- Asia Consortium Executive Committee
- Asia Consortium Advisory Committee
- Asia Pacific Conference Committee
- Asia Consortium Education Committee
- Asia Consortium Publication Committee
- Asia Consortium Industry Committee
- Asia Consortium HTA Agencies Committee
- HealthNetIndia
- Central & Eastern Europe Consortium
- Latin America Consortium
-
Asia Consortium
- Networks
- Regional Chapters
-
Join an ISPOR Global Member Group
-
Consortia
- Students
-
New Professionals
-
Professional Development Resources
- Good Practices for HTA - What is out there and how do I use it
- ISPOR & AACP Joint Webinar – “Tips for Securing a Post-Doctoral Fellowship”
- You Are Creative: Research is the First Step
- AMCP eDossier System @ FormularyDecisions.com Demo and Practical Application
- Good Practices for a Successful Job Search
- Leveraging The Power Of LinkedIn
- Internships & Fellowships: Career Opportunities for the Future
- My Career Path
- Career Advice Across the Globe
- "My ISPOR Story" - Zeba Khan
- "My ISPOR Story" - Lou Garrison
-
Professional Development Resources
Mission
To develop good practices for outcomes research in the study design and utilization of genomics involved in personalized/precision medicine.
Background
The term "personalized medicine" is often described as providing "the right patient with the right drug at the right dose at the right time. More broadly, personalized medicine (also known as precision medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up.
Leadership:
Emily Reese, PhD MPH
Molly Purser, MBA BS PhD
Working Groups:
Key Project
Being precise about precision medicine: What should value frameworks incorporate to address precision medicine? - A report of the Personalized Precision Medicine Special Interest Group
Submitted to Value in Health
Real-world evidence to address uncertainty for transformative and curative therapies
Co-chairs:
- Eric Faulkner, MPH, Vice President, Real World Value and Strategy, Executive Director, Precision and Transformative Medicine Center of Excellence, Evidera
- Sue Zelt, DrPH, Principal and consultant, Cere Health Research
Member Engagement:
Journal Club
We will hold 4 meetings each year. Each journal club will commence with a brief overview of the article by the author, followed by a moderated discussion of the article.
Chair:
- Melanie D. Whittington, PhD, Research Assistant Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
November 15 at 11:00 AM EDT “A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine” by Garrison and Towse
Others TBD